Navigation Links
GeneLink Biosciences Completes Sale of GeneWize Life Sciences
Date:2/16/2012

ORLANDO, Fla., Feb. 16, 2012 /PRNewswire/ -- GeneLink Biosciences, Inc. (OTCBB: GNLK), a leading consumer genomics biotech company, has completed the sale of the stock of its wholly owned direct-selling subsidiary GeneWize Life Sciences, Inc. (GeneWize)  to Capsalus Corp. (OTCBB: WELL), another public company operating in the health and wellness marketplace.  As previously disclosed, GeneLink and Capsalus executed definitive agreements for the sale of GeneWize on October 13, 2011 and GeneLink obtained shareholder approval of the transaction at a Special Shareholders Meeting on January 25, 2012.

GeneLink is a leader in consumer genomics, combining genetic science, wellness and customization to create innovative consumer products, including skincare and nutritional supplements personalized to reflect important elements of the individual customer's genetic profile. Through its operation of GeneWize, GeneLink has generated more than $25 million in revenues over the past three years, demonstrating the commercial viability of these DNA-customized products.

"The sale of GeneWize is an important step in GeneLink's strategy of leveraging the strengths of its sales and marketing partners in order to focus on the company's core competencies, and thus accelerate its growth," said Bernard L. Kasten Jr., M.D., GeneLink's Chairman and CEO.   "We are already impressed with the commitment and resources which Capsalus and its partners are bringing to GeneWize.  We would like nothing more than to see GeneWize and its brand partners flourish while supporting and selling GeneLink's genetic assessments and genetically influenced consumer products."

GeneLink Biosciences, Inc. (www.genelinkbio.com) is a 17-year old leading biosciences company specializing in consumer genomics. GeneLink's patented technologies include proprietary DNA assessments linked to personalized health, beauty and wellness applications and products. Its DNA assessments provide information that enables the customization of nutritional and skincare products designed and manufactured to fulfill each individual consumer's wellness needs.

Forward-looking Statements

This news release may contain "Forward-looking Statements" within the meaning of Section 21E of the United States Securities Exchange Act, as amended.  All statements in this news release, other than statements of historical fact, are forward-looking statements that involve various risks and uncertainties.  There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements.  This notice expressly qualifies all forward-looking statements in this news release.


'/>"/>
SOURCE GeneLink Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GeneLink Marketing Efforts Poised to Show Results
2. GeneLink BioSciences, Inc. Ranked Number 33 Fastest Growing Company in North America on Deloittes 2011 Technology Fast 500™
3. GeneLink Reports Second Quarter 2011 Results
4. GeneLink Biosciences Expands its Scientific Advisory Board to Support New Product Lines
5. GeneLink Reports Denial of Appeal
6. GeneLink Reports 2010 Results
7. GeneLink Announces New Licensing Partner
8. GeneLink Reports Third Quarter Results
9. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
10. GeneLink Announces HelixLife Private Label Distribution Agreement
11. GeneLink Reports First Quarter Gains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... February 11, 2016 ... or "Company") (OTCQB: PSID), a life sciences company ... its Thermomedics subsidiary, which markets the Caregiver® FDA-cleared ... plan in January 2016, including entering into agreements ... monthly sales growth, and establishing several near-term pipeline ...
(Date:2/11/2016)... ... 11, 2016 , ... Global Stem Cells Group, ... Ecuador. The new facility will provide advanced protocols and state-of-the-art techniques in cellular ... , The new GSCG clinic is headed by four prominent Ecuadorian physicians, ...
(Date:2/10/2016)... LOUISVILLE, Ky. , Feb. 10, 2016 ... company utilizing its proprietary NeXosome® technology for early ... presentation of its most recent study by Dr. ... Hospital at the Society for Maternal Fetal Medicine,s (SMFM) ... , GA, February 1-6 th , 2016.  The presentation ...
(Date:2/10/2016)... Feb. 10, 2016  Allergan plc (NYSE: AGN ... Brent Saunders , Allergan,s CEO and President, will ... chat session at the RBC Capital Markets Healthcare Conference ... at The New York Palace Hotel in ... webcast live and can be accessed on Allergan,s Investor ...
Breaking Biology Technology:
(Date:2/9/2016)... Feb. 9, 2016 Vigilant Solutions announces today that ... (LPR) to develop a lead in a difficult homicide case. ... data to locate the suspect vehicle. Due to the ongoing ... have been omitted at the agency,s request. ... explains, "Our victim was found deceased at an intersection here ...
(Date:2/5/2016)... , Feb. 5, 2016 ... of the "Global Facial Recognition Market ... --> http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the ... Market 2016-2020" report to their offering. ... http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the addition of ...
(Date:2/3/2016)... February 4, 2016 --> --> ... 1,351.5 M (105.0), up 1,187% compared with fourth quarter of 2014. ... SEK 517.6 M (loss: 30.0). Earnings per share increased to ... SEK 537.4 M (neg: 74.7). , --> ... amounted to SEK 2,900.5 M (233.6), up 1,142% compared with 2014. ...
Breaking Biology News(10 mins):